open access

Vol 6, No 1 (2005): Practical Diabetology
Original articles (submitted)
Published online: 2005-02-17
Get Citation

Efficacy, tolerability, and safety of Amaryl (glimepiride). Multicenter, retrospective, polish cohort study

Ida Kinalska, Jan M. Wójcicki
Diabetologia Praktyczna 2005;6(1):21-28.

open access

Vol 6, No 1 (2005): Practical Diabetology
Original articles (submitted)
Published online: 2005-02-17

Abstract

INTRODUCTION. Glimepiride is indicated for the treatment of type 2 diabetes mellitus. The aim of the present study was to monitor the tolerability and efficacy of glimepiride in Polish diabetic patients in daily practice.
MATERIAL AND METHODS. A 12-week non interventional cohort study in daily practice was performed. 2587 patients with type 2 diabetes mellitus were included into the study. The patients were treated with glimepiride for at least 3 months. In patients with pre-existing oral antihyperglicaemic medication the therapy was changed to glimepiride monotherapy.
RESULTS. The mean reduction of HbA1c (0.95%) was more significant in newly treated patients with glimepiride. Body weight was reduced (0.5 BMI). This effect was particulary observed in the obese patients. In 3,7% patients adverse events were observed including hypoglicaemia (0.64%).
CONCLUSION. This study carried out in Poland under daily practice confirmed the good tolerability and efficacy of glimepiride in the treatment of diabetic patients.

Abstract

INTRODUCTION. Glimepiride is indicated for the treatment of type 2 diabetes mellitus. The aim of the present study was to monitor the tolerability and efficacy of glimepiride in Polish diabetic patients in daily practice.
MATERIAL AND METHODS. A 12-week non interventional cohort study in daily practice was performed. 2587 patients with type 2 diabetes mellitus were included into the study. The patients were treated with glimepiride for at least 3 months. In patients with pre-existing oral antihyperglicaemic medication the therapy was changed to glimepiride monotherapy.
RESULTS. The mean reduction of HbA1c (0.95%) was more significant in newly treated patients with glimepiride. Body weight was reduced (0.5 BMI). This effect was particulary observed in the obese patients. In 3,7% patients adverse events were observed including hypoglicaemia (0.64%).
CONCLUSION. This study carried out in Poland under daily practice confirmed the good tolerability and efficacy of glimepiride in the treatment of diabetic patients.
Get Citation

Keywords

diabetes mellitus type 2; glimepiride; observentional cohort study

About this article
Title

Efficacy, tolerability, and safety of Amaryl (glimepiride). Multicenter, retrospective, polish cohort study

Journal

Clinical Diabetology

Issue

Vol 6, No 1 (2005): Practical Diabetology

Pages

21-28

Published online

2005-02-17

Bibliographic record

Diabetologia Praktyczna 2005;6(1):21-28.

Keywords

diabetes mellitus type 2
glimepiride
observentional cohort study

Authors

Ida Kinalska
Jan M. Wójcicki

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl